Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
15.46
-0.62 (-3.86%)
At close: Mar 12, 2026, 4:00 PM EDT
15.43
-0.03 (-0.19%)
After-hours: Mar 12, 2026, 7:58 PM EDT
Summit Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts that cover Summit Therapeutics stock have a consensus rating of "Buy" and an average price target of $33.38, which forecasts a 115.91% increase in the stock price over the next year. The lowest target is $12 and the highest is $44.
Price Target: $33.38 (+115.91%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Summit Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 8 | 7 | 7 | 7 |
| Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Hold | 1 | 2 | 3 | 3 | 3 | 3 |
| Sell | 2 | 2 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 18 | 16 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $30 | Strong Buy | Maintains | $40 → $30 | +94.05% | Feb 24, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +158.73% | Feb 2, 2026 |
| Citizens | Citizens | Buy Reiterates $40 | Buy | Reiterates | $40 | +158.73% | Jan 30, 2026 |
| Barclays | Barclays | Sell → Hold Upgrades $16 → $18 | Sell → Hold | Upgrades | $16 → $18 | +16.43% | Dec 17, 2025 |
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Nov 18, 2025 |
Financial Forecast
Revenue This Year
9.71M
Revenue Next Year
110.00M
from 9.71M
Increased by 1,032.97%
EPS This Year
-1.02
from -1.44
EPS Next Year
-1.01
from -1.02
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 61.0M | 377.9M | |||
| Avg | 9.7M | 110.0M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 3,792.0% | |||
| Avg | - | 1,033.0% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.60 | -0.61 | |||
| Avg | -1.02 | -1.01 | |||
| Low | -1.60 | -1.65 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.